StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
25
This month
1
This week
1
This year
5
Publishing Date
2024 - 04 - 15
1
2024 - 02 - 06
2
2024 - 02 - 05
1
2024 - 01 - 25
1
2023 - 09 - 25
1
2023 - 09 - 04
1
2023 - 07 - 31
1
2023 - 07 - 06
1
2022 - 04 - 20
1
2021 - 12 - 01
1
2021 - 10 - 26
1
2021 - 10 - 18
1
2021 - 09 - 27
1
2021 - 09 - 09
1
2021 - 09 - 07
1
2021 - 08 - 23
2
2021 - 07 - 13
1
2021 - 06 - 10
1
2021 - 05 - 19
1
2021 - 03 - 08
1
2021 - 02 - 17
1
2021 - 01 - 21
1
2020 - 12 - 09
1
Sector
Health technology
25
Tags
Alvelestat
1
Application
1
Approval
7
Biopharma
1
Biotech-bay
3
Biotechnology
1
Brazil
2
Canada
1
Canada approval
1
Children
3
Clearance
3
Clinical hold
1
Clinical-trials-phase-ii
2
Collaboration
1
Designation
3
Disease
7
Drug
4
Europe
1
Evkeeza
1
Fda
3
Fda clearance
2
Gene therapies
1
Gene therapy
2
Global
1
Growth
1
Gtx-102
2
Hypercholesterolemia
1
Injection
1
Media
3
Metabolic
1
N/a
18
New drug
2
Orphan drug
1
Phase 1
2
Phase 2
1
Positive
1
Prime
1
Program
1
Rare
1
Research
1
Results
1
Study
1
Syndros
3
Therapy
6
Treatment
25
Trial
2
Ux111
2
Ux143
2
Ux701
2
Entities
3m company
21
Abbott laboratories
60
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
51
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
208
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
65
Moleculin biotech, inc.
28
Novartis ag
144
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
21
Pfizer, inc.
74
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
293
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
53
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
AMGN
1
KIDS
1
LLY
1
MREO
4
RARE
25
REGN
1
TEVJF
1
VTRS
1
Exchanges
Nasdaq
25
Nyse
1
Crawled Date
2024 - 04 - 15
1
2024 - 02 - 06
2
2024 - 02 - 05
1
2024 - 01 - 25
1
2023 - 09 - 25
1
2023 - 09 - 04
1
2023 - 07 - 31
1
2023 - 07 - 06
1
2022 - 04 - 20
1
2021 - 12 - 01
1
2021 - 10 - 26
1
2021 - 10 - 18
1
2021 - 09 - 27
1
2021 - 09 - 09
1
2021 - 09 - 07
1
2021 - 08 - 23
2
2021 - 07 - 13
1
2021 - 06 - 10
1
2021 - 05 - 19
1
2021 - 03 - 08
1
2021 - 02 - 17
1
2021 - 01 - 21
1
2020 - 12 - 09
1
Crawled Time
08:00
2
11:00
1
12:00
1
12:15
1
12:20
1
13:00
6
14:00
2
14:01
2
14:15
1
15:00
1
16:00
2
17:00
1
21:00
3
21:06
1
Source
www.biospace.com
7
www.globenewswire.com
17
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Ultragenyx pharmaceutical inc.
save search
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published:
2024-04-15
(Crawled : 11:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-11.65%
|
O:
-10.79%
H:
0.0%
C:
-3.75%
gtx-102
positive
treatment
Ultragenyx Announces Data Demonstrating Treatment with UX111
Published:
2024-02-06
(Crawled : 14:00)
- biospace.com/
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-1.45%
|
O:
0.67%
H:
2.0%
C:
1.84%
ux111
treatment
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
Published:
2024-02-06
(Crawled : 13:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-1.45%
|
O:
0.67%
H:
2.0%
C:
1.84%
ux111
treatment
results
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
Published:
2024-02-05
(Crawled : 21:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-1.45%
|
O:
0.67%
H:
2.0%
C:
1.84%
gtx-102
treatment
designation
prime
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published:
2024-01-25
(Crawled : 21:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-2.52%
|
O:
0.55%
H:
1.01%
C:
-1.16%
ux701
disease
treatment
therapy
study
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Published:
2023-09-25
(Crawled : 21:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
20.29%
|
O:
0.46%
H:
4.26%
C:
1.55%
REGN
|
$893.66
-0.84%
-0.84%
450K
|
Health Technology
|
7.97%
|
O:
0.04%
H:
0.65%
C:
-0.31%
evkeeza
treatment
hypercholesterolemia
canada
Addressing the Fragile: 2023 Global Osteogenesis Imperfecta Treatment Market's Growth Driven by Research and Collaboration
Published:
2023-09-04
(Crawled : 16:00)
- prnewswire.com
MREO
|
$2.66
3.1%
3.01%
810K
|
Health Technology
|
Email alert
Add to watchlist
VTRS
|
$11.11
0.09%
0.09%
3.5M
|
Health Technology
|
Email alert
Add to watchlist
KIDS
|
$29.485
-1.39%
-1.41%
81K
|
Health Technology
|
Email alert
Add to watchlist
LLY
|
News
|
$745.95
-0.64%
-0.1%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
AMGN
|
$262.77
-0.49%
-0.49%
2M
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
Email alert
Add to watchlist
treatment
research
global
collaboration
growth
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published:
2023-07-31
(Crawled : 16:00)
- biospace.com/
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
2.32%
|
O:
0.81%
H:
1.93%
C:
-0.78%
ux701
disease
treatment
trial
therapy
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Published:
2023-07-06
(Crawled : 12:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-5.0%
|
O:
-1.06%
H:
0.24%
C:
-0.91%
MREO
|
$2.66
3.1%
3.01%
810K
|
Health Technology
|
101.56%
|
O:
-2.34%
H:
2.0%
C:
-1.6%
ux143
treatment
program
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
Published:
2022-04-20
(Crawled : 12:20)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-44.02%
|
O:
-0.15%
H:
1.14%
C:
0.06%
MREO
|
$2.66
3.1%
3.01%
810K
|
Health Technology
|
195.53%
|
O:
3.09%
H:
0.0%
C:
-9.78%
ux143
treatment
phase 2
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
Published:
2021-12-01
(Crawled : 15:00)
- biospace.com/
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-41.37%
|
O:
0.25%
H:
3.1%
C:
0.98%
treatment
disease
phase 1
therapy
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency
Published:
2021-10-26
(Crawled : 14:15)
- biospace.com/
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-44.65%
|
O:
1.29%
H:
0.0%
C:
0.0%
MREO
|
$2.66
3.1%
3.01%
810K
|
Health Technology
|
18.89%
|
O:
-0.46%
H:
0.0%
C:
0.0%
treatment
biopharma
orphan drug
drug
designation
alvelestat
Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published:
2021-10-18
(Crawled : 17:00)
- biospace.com/
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-44.86%
|
O:
-1.4%
H:
0.27%
C:
-1.09%
disease
treatment
gene therapy
therapy
trial
GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.
Published:
2021-09-27
(Crawled : 13:00)
- biospace.com/
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-53.62%
|
O:
-0.07%
H:
0.34%
C:
-6.71%
treatment
fda
phase 1
clinical hold
syndros
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
Published:
2021-09-09
(Crawled : 08:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-56.88%
|
O:
-0.58%
H:
2.56%
C:
-0.46%
media
treatment
approval
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults
Published:
2021-09-07
(Crawled : 12:15)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-56.12%
|
O:
1.8%
H:
1.99%
C:
-0.35%
canada approval
media
treatment
injection
approval
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenDojolvi is the only approved therapy for this rare, life-threatening metabolic disorder
Published:
2021-08-23
(Crawled : 13:00)
- biospace.com/
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-43.25%
|
O:
4.68%
H:
4.22%
C:
4.04%
treatment
brazil
therapy
metabolic
children
approval
rare
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
Published:
2021-08-23
(Crawled : 13:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-43.25%
|
O:
4.68%
H:
4.22%
C:
4.04%
treatment
brazil
children
approval
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
Published:
2021-07-13
(Crawled : 08:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-51.73%
|
O:
-0.16%
H:
2.26%
C:
-4.01%
media
treatment
approval
GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome
Published:
2021-06-10
(Crawled : 13:00)
- globenewswire.com
RARE
|
$43.38
-1.65%
-1.68%
770K
|
Health Technology
|
-53.26%
|
O:
0.2%
H:
8.89%
C:
5.07%
treatment
approval
syndros
← Previous
1
2
Next →
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.